No increase in CV events in Januvia trial

10 June 2015
merck-700

US pharma giant Merck & Co (NYSE: MRK) has announced the primary results of a placebo-controlled study of the cardiovascular safety of its DPP-4 inhibitor, Januvia (sitagliptin).

This already marketed drug generated first-quarter 2015 sales of $1.39 billion for Merck.

The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study achieved its primary composite CV endpoint of non-inferiority compared to usual care without sitagliptin. Non-inferiority was defined as the time to the first confirmed event of any of the following: CV-related death, nonfatal myocardial infarction (MI), nonfatal stroke, or hospitalization for unstable angina.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical